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Abstract
Background: The large-scale deployment of antiviral drugs from the Strategic National Stockpile during the 2009
H1N1 influenza response provides a unique opportunity to study local public health implementation of the
medical countermeasure dispensing capability in a prolonged event of national significance. This study aims to
describe the range of methods used by local health departments (LHDs) in California to manage antiviral activities
and to gain a better understanding of the related challenges experienced by health departments and their
community partners.
Methods: This research employed a mixed-methods approach. First, a multi-disciplinary focus group of pandemic
influenza planners from key stakeholder groups in California was convened in order to generate ideas and identify
critical themes related to the local implementation of antiviral activities during the H1N1 influenza response. These
qualitative data informed the development of a web-based survey, which was distributed to all 61 LHDs in
California for the purpose of assessing the experiences of a representative sample of local health agencies in a
large region.
Results: Forty-four LHDs participated in this study, representing 72% of the local public health agencies in
California. While most communities dispensed a modest number of publicly purchased antivirals, LHDs nevertheless
drew on their previous work and engaged in a number of antiviral activities, including: acquiring, allocating,
distributing, dispensing, tracking, developing guidance, and communicating to the public and clinical community.
LHDs also identified specific antiviral challenges presented by the H1N1 pandemic, including: reconciling multiple
sources and versions of antiviral guidance, determining appropriate uses and recipients of publicly purchased
antivirals, and staffing shortages.
Conclusions: The 2009 H1N1 influenza pandemic presented an unusual opportunity to learn about the role of
local public health in the management of antiviral response activities during a real public health emergency.
Results of this study offer an important descriptive account of LHD management of publicly purchased antivirals,
and provide practitioners, policy makers, and academics with a practice-based assessment of these events. The
issues raised and the challenges faced by LHDs should be leveraged to inform public health planning for future
pandemics and other emergency events that require medical countermeasure dispensing activities.
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On April 26, 2009, the United States Government
declared a public health emergency in response to the
threat posed by the 2009 H1N1 influenza virus, A
(H1N1)pdm09 [1]. This declaration triggered the Cen-
ters for Disease Control and Prevention (CDC) to ship
large quantities of medical provisions from the Strategic
National Stockpile (SNS) to state health departments
around the nation in an effort to mitigate and control
outbreaks of the novel virus. Included in this shipment
were 11 million regimens of antiviral drugs (two neura-
minidase inhibitors, oseltamivir and zanamivir), which
were later accompanied by new federal guidance on the
recommended clinical use of these drugs during the
pandemic [2,3]. These events prompted state and local
health departments to make decisions regarding how
and where publicly purchased antivirals would be used
in their communities to treat ill persons and slow the
spread of disease.
The large-scale deployment of antivirals during the
H 1 N 1i n f l u e n z ar e s p o n s ep r e s e n t e dau n i q u eo p p o r t u -
nity to study the local public health implementation of
plans and protocols to support medical countermeasure
dispensing. As one of the CDC public health emergency
capabilities, Medical Countermeasure Dispensing is
defined as, “the ability to provide medical countermea-
sures (including vaccines, antiviral drugs, antibiotics,
antitoxin, etc.) in support of treatment or prophylaxis...
to the identified population in accordance with public
health guidelines and/or recommendations” [4]. The
H1N1 influenza pandemic offered a highly unusual
situation in which state and local health departments
across the country simultaneously carried out this func-
tion during a prolonged event of national significance.
The need for the public health management of anti-
viral drugs during an influenza pandemic did not take
public health officials by surprise. Prior to 2009, public
health agencies and community partners had been
actively engaged in preparedness activities in anticipa-
tion of antiviral utilization during an influenza pan-
demic. Among those efforts were large-scale purchase of
antiviral drugs and the development of plans to appro-
priately use these medications to treat influenza illness
and to reduce the impact of a pandemic [5]. However,
given few opportunities to observe real-world response
to an influenza pandemic, the preparedness commu-
nity’s understanding of state and local readiness for
implementing a large-scale antiviral program has been
limited. As a result, pre-pandemic assessments have
reached wide-ranging conclusions regarding this prepa-
redness capacity. In 2008, a federal assessment of pan-
demic influenza State Operating Plans found that “there
are very few gaps in State readiness for antiviral drug
distribution” [6]. Just one year later, the U.S. Depart-
ment of Health and Human Services (HHS) Office of
Inspector General reported notable gaps in antiviral
plans at the local level, despite high scores in antiviral
preparedness at the state level [7]. While these reports
may, at first, seem contradictory, the findings illuminate
the differences in the roles, responsibilities, and capaci-
ties of health departments at the state and local levels.
For many states, including California, the primary
responsibility for managing local antiviral drug activities
resides with Local Health Departments (LHDs) in order
to enable local control, planning, and implementation
[8-10].
The 2009 H1N1 influenza response provided a valu-
able opportunity to learn from the experiences of LHDs
during a real public health emergency. While the
demand for antiviral drugs during the 2009 H1N1 influ-
enza response was not as dramatic as had been pre-
dicted in many pre-pandemic planning scenarios [5,11],
this paper seeks to illuminate how LHDs nevertheless
drew on their previous work to meet the needs for anti-
viral drugs within their community. The H1N1 pan-
demic also tested antiviral planning assumptions and
forced LHDs to creatively respond to new and unex-
pected challenges. The purpose of this study, then, is to
describe the range of methods used by LHDs in Califor-
nia to manage antiviral activities and to gain a better
understanding of the related challenges experienced by
health departments and their community partners, with
the goal of informing future planning for local public
health preparedness and response efforts.
Methods
This research employed a mixed-methods approach.
First, a multi-disciplinary focus group of pandemic influ-
enza planners from key stakeholder groups in California
was convened in order to generate ideas and identify
critical themes related to the local implementation of
antiviral activities during the H1N1 influenza response.
These qualitative data informed the development of a
web-based survey, which was distributed to all 61 LHDs
in California, for the purpose of assessing experiences of
LHDs from a representative sample of local health agen-
cies in California.
Phase I - focus group
The first phase consisted of a teleconference-based focus
group, comprised of members of the California Pan-
demic Influenza Vaccine and Antiviral (PIVA) Advisory
Group. This statewide advisory group of pandemic plan-
ners and experts had convened prior to the 2009 H1N1
pandemic for the purpose of providing the California
Department of Public Health with recommendations
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an influenza pandemic [12,13]. All PIVA Advisory
Group members were invited to participate in the focus
group via email, and were provided with an agenda that
included an overview of focus group topics prior to the
teleconference. The focus group topics included ques-
tions about antiviral acquisition, dispensing, and use.
Also included were questions regarding challenges that
were faced in these areas.
The focus group took place by phone in July 2010 and
lasted 120 minutes. Twenty-three advisory group mem-
bers participated in the teleconference, including repre-
sentatives from state and local public health
departments, federal agencies, private sector associa-
tions, academic institutions, hospitals, law enforcement
agencies, and non-governmental organizations. The
focus group was facilitated by one primary and one sec-
ondary facilitator. Notes were taken by the facilitators
and an additional note taker, and were transcribed and
merged into one document for review before being pro-
vided to focus group participants for participant valida-
tion. The focus group notes were reviewed to distill any
relevant information that could be used to improve and
strengthen the survey.
Phase II - web-based survey
In the second phase of the study, a web-based survey
was distributed to all 61 LHDs in California. This survey
covered, in greater detail, the same antiviral topics dis-
cussed in the focus group informed by: focus group
input, literature reviews, pre-pandemic planning with
the PIVA Advisory Group, experiences of study person-
nel, and pilot testing with practice-based and academic-
based experts. LHD involvement in the planning, coor-
dination, and implementation of activities related to
publicly purchased antivirals (i.e. those purchased by
state or federal entities) were assessed in the following
survey domains:
￿ Acquiring, distributing, allocating, dispensing, and
use of antivirals;
￿ Tracking and monitoring the use of antivirals;
￿ Communications with other organizations regarding
antivirals; and
￿ Challenges faced by LHDs in any of the aforemen-
tioned areas.
All LHDs within the state of California were recruited
for participation in the survey, with the goal of obtaining
a representative sample of LHDs’ experiences managing
antivirals during the H1N1 influenza response. A com-
plete list of current LHD Health Officers and SNS Coor-
dinators for each of the 61 LHDs in California (58
county health departments and 3 independent municipal
health departments) was obtained from the California
Department of Public Health. Based on the focus group
discussion, persons in these two functional roles were
expected to be most knowledgeable about the antiviral
response at the local level.
The survey invitation was distributed to Health Offi-
cers and SNS Coordinators for all 61 LHDs along with a
short description of the survey goals via email from the
office of the Principal Investigator of Cal PREPARE, a
CDC Preparedness and Emergency Response Research
Center at the University of California, Berkeley. Recipi-
ents were instructed to forward the survey to the person
within their department who was most informed about
the health department’s H1N1 influenza antiviral
response and to submit one response for their health
department. Survey data collection took place over the
course of 3 weeks in August and September 2010. Two
reminders were sent to invited participants via email in
order to increase response rates.
Survey data were downloaded from the web survey
provider and merged with county demographic data.
Demographic data for the LHD catchment areas were
collected from publicly available sources in order to
classify LHDs by population size and to make compari-
sons of responding and non-responding agencies [14].
Health departments were classified into one of three
population size categories based on the number of indi-
viduals served, adopting a categorization convention
used by the National Association of County and City
Health Officials: (1) fewer than 50,000 people, (2)
between 50,000 and 499,999 people, and (3) 500,000 or
more people [15]. Data were analyzed in Stata 11 (Stata-
Corp LP, College Station, TX). A descriptive analysis of
the survey results is presented here with quotations
from the focus group and the survey to illustrate salient
issues.
The protocol for this study was approved by the Com-
mittee for Protection of Human Subjects at the Univer-
sity of California, Berkeley.
Results
These results describe the data obtained from LHD staff
through the web-based survey.
Sample demographics
Sixty-one LHDs were invited to participate in this study.
Forty-four local health departments completed the sur-
vey, resulting in a 72% response rate. These counties
represent 74% of the population of California. Participat-
ing agencies did not statistically differ from non-partici-
pating agencies with respect to the size of population
served by the health department (chi-square with two
degrees of freedom = 5.64, p = 0.35) or median house-
hold income (t = 0, p = 0.60). There was a borderline
significant difference in the geographic distribution of
responding counties (chi-square with two degrees of
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in the southern region (46%) compared to the inland
region (81%) and the coastal region (76%) [16].
The most widely represented functional role for
respondents was SNS coordinators, with 55% identifying
themselves as such. Other common functional roles
were Emergency Preparedness Coordinator/Director and
Health Officer with 25% and 27%, respectively (respon-
dents could choose more than one functional role).
Ninety eight percent of respondents stated that they
were very knowledgeable about their LHD’s antiviral
activities during 2009 H1N1 response and 2% reported
being somewhat knowledgeable about their LHD’s
response. Survey respondents who indicated that they
knew only “a little” about their LHD’sa n t i v i r a lr e s p o n s e
were not allowed to complete the survey. Two respon-
dents fell into this category and were not included in
the overall response rate.
Acquiring, distributing and allocating antivirals
Acquiring antivirals
All LHDs received antivirals from state or federal stock-
piles, with a few LHDs receiving antivirals from a local
cache or purchasing antivirals directly from the com-
mercial or retail market as well. In this report, those
antivirals purchased by state or federal government
agencies for public use will be referred to as “publicly
purchased antivirals” or “state and federal stockpiles.”
Distributing antivirals
Twenty-eight LHDs reported distributing publicly pur-
chased antivirals to other organizations for dispensing to
the public, which accounts for 64% of respondents. The
organizations and agencies that received antiviral drugs
from LHDs are presented in Table 1. Among those
most frequently cited were clinics, hospitals, and phar-
macies (71%, 64%, and 54%, respectively). While many
LHDs distributed antivirals to hospitals, others found
that hospital pharmacies were unable to accept publicly
purchased antivirals, as described by one participant,
“We contracted with [chain retail pharmacy] for this
service since hospitals could not accept public anti-
virals into their pharmacies.”
Receiving organizations classified under “Other”
include HIV care providers, addiction programs, home-
less centers and children’s homes.
Allocating antivirals
LHDs selected organizations to dispense publicly pur-
chased antivirals for the following reasons: to reach the
uninsured or underinsured (89%), to reach severely ill
persons (61%), to reach medically at-risk persons such
as pregnant women (57%), and/or because the
organization was well-known in the community (61%).
LHDs also noted that dispensing sites were chosen
based on storage capacity or the ability of a pharmacy
to correctly reconstitute antiviral suspension for
children.
The number of antivirals allocated to these dispensing
sites was determined based on the characteristics of the
patient population served (41%), requests for antivirals
(37%), number of persons served by a medical or treat-
ment facility (33%), and/or epidemiologic data and
patient volume (26%).
Eight of the 28 LHDs that distributed antivirals to
other organizations for dispensing to the public reported
that they required facilities to show that antivirals were
not commercially available before they could receive
publicly purchased antivirals (28%). This strategy was
based on the rationale that publicly purchased antivirals
should be used only as a last resort after the commercial
and retail markets had been depleted.
Antiviral dispensing, use and shortages
Antiviral dispensing
Thirty-one LHDs reported that publicly purchased anti-
virals were dispensed for patient use in their jurisdiction
(70%). Of these LHDs, approximately 90% dispensed
fewer than 250 doses of antivirals (ranging from less
than 100 doses to more than 10,000 doses). On average,
the reported number of antiviral doses dispensed in a
community increased with population size. For small
LHDs serving fewer than 50,000 residents, the modal
number of antiviral doses dispensed was 0 doses (ran-
ging from 0 to 250 doses); for medium LHDs serving a
population of 50,000-499,999, the modal number of
antiviral doses dispensed was less than 250 doses (ran-
ging from 0 to 1,000 doses); and for large LHDs serving
a population of 500,000 and more, the modal number
was less than 250 doses (ranging from 0 to more than
10,000 doses). For those LHDs reporting that publicly
stockpiled antivirals were not dispensed in their jurisdic-
tion, many reported that they had few influenza cases
and demand for antivirals was low. Others indicated
that their strategy was to use publicly purchased antivir-
als when shortages were reported in the local commer-
cial market, which did not occur in their communities.
All LHDs that distributed publicly purchased antivirals
to dispensing sites required those organizations to agree
to certain terms of dispensing. Eighty six percent of
these 28 LHDs required dispensing sites to track anti-
viral utilization and report it to the health department.
Providing antivirals free of charge to the uninsured or
underinsured and providing antivirals free of charge to
all were required by 61% and 50% of these LHDs,
respectively. Other requirements noted by respondents
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lowing current recommendations for use, requesting
documentation from recipients to ensure eligibility, and
the use of temperature-controlled storage.
Antiviral use
Potential uses of antiviral drugs include treatment, pre-
exposure prophylaxis, and post-exposure prophylaxis.
LHDs were asked about allowable uses for publicly pur-
chased antivirals in their community and the target
groups for each allowable use (Tables 2, 3 and 4). In
addition to the target groups presented in Tables 3 and
4, several LHDs further specified that restrictions on
populations eligible for publicly purchased antivirals for
treatment were lifted when antivirals were not commer-
cially available. Regarding prophylaxis, LHDs noted that
publicly purchased antivirals were dispensed to unin-
sured or underinsured persons, children, and household
members of ill persons early in the pandemic in order
to slow transmission of the virus.
In order to determine eligibility to receive publicly
purchased antivirals, 24 of the 31 LHDs reporting that
publicly purchased antivirals were dispensed for patient
use in their jurisdiction instituted verification proce-
dures. Fifty four percent of theses LHDs reported using
pharmacists or dispensing sites to determine eligibility
status, 46% reported that physicians provided proof of
eligibility, and 25% indicated that patients self-reported
their eligibility status. Six LHDs did not require any elig-
ibility verification.
Antiviral shortages
Among all LHD respondents, 26 indicated that their
communities experienced shortages of at least one type
of antiviral drug (60%). Shortages were primarily of
pediatric formulation of oseltamivir, followed by adult
formulation of oseltamivir (reported by 96% and 38% of
LHDs with shortages, respectively). No shortages of
zanamivir or peramivir were reported.
Antiviral tracking and monitoring
LHDs were asked about their ability to track the move-
ment of antivirals from stockpile sites to recipients. Of
the 28 health departments that distributed antivirals,
nearly all were able to track the federal/state stockpile
to their health department (93%), and from the health
Table 1 Number of LHDs that distributed antivirals to other organizations for dispensing to public (n = 28).
Size of Population Served by LHD
Small (< 50,000) Medium (50,000-499,999) Large (500,000+) All LHDs
Organization/Entity n (%) n (%) n (%) n (%)
Public clinics/Health Centers 2 (50) 11 (69) 7 (88) 20 (71)
Private hospitals 0 (0) 10 (63) 8 (100) 18 (64)**
Retail pharmacies 3 (75) 8 (50) 4 (50) 15 (54)
Public Hospitals 2 (50) 3 (19) 8 (100) 13 (46)
Private clinicians 0 (0) 5 (31) 4 (50) 9 (32)
Tribal health clinic/hospitals 1 (25) 4 (25) 3 (38) 8 (29)
Prisons 0 (0) 1 (6) 4 (50) 5 (18)
College/Universities 0 (0) 4 (25) 1 (13) 5 (18)
Direct to patient* 0 (0) 3 (19) 2 (25) 5 (18)
Skilled nursing facilities/Long term care facilities 1 (25) 1 (6) 2 (25) 4 (14)
Military bases 0 (0) 0 (0) 0 (0) 0 (0)
Airports 0 (0) 0 (0) 0 (0) 0 (0)
Other 1 (25) 3 (19) 1 (13) 5 (18)
Total 4 16 8 28
Among the twenty-eight local health departments (LHDs) that distributed publicly purchased antivirals to other organizations for dispensing to the public, Table
1 summarizes the number and proportion of LHDs that reported distributing antivirals to each type of organization or entity, stratified by size of population
served by LHD
*Direct to patient methods include household delivery and pick-up and health department
**Indicates statistically significant difference with respect to population size served by LHD (Fisher’s exact test, p < .05)
Table 2 Allowable uses for publicly purchased antivirals
(n = 31).
Allowable Use n (% of LHDs)
Treatment of ill persons 28 (90)
Post-Exposure Prophylaxis (PEP) 24 (77)
Pre-Exposure Prophylaxis (PrEP) 7 (23)
Allowable use determined by dispensing site 8 (26)
Other 2 (6)
Among the thirty-one local health departments (LHDs) reporting that publicly
purchased antivirals were dispensed in their community, Table 2 summarizes
the number and proportion of LHDs that allowed publicly purchased antivirals
to be used for treatment, post-exposure prophylaxis, and pre-exposure
prophylaxis
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able to track from dispensing sites to recipients (71%).
Twenty-four LHDs received antiviral utilization data
from dispensing sites with varying degrees of frequency.
Half of these LHDs received antiviral utilization reports
weekly or more frequently. Some health departments
received basic utilization data, such as number of
courses dispensed or lot numbers, while others received
more specific data, including demographic information,
intended use of antivirals (e.g. treatment, PEP), or rea-
son that public stockpiles were utilized (e.g. shortages,
uninsured recipient). These data were primarily used for
making allocation decisions, surveillance, future antiviral
planning, reaching target populations, and providing
data to other agencies. Utilization data were received
primarily by fax, but also by email, phone calls, face-to-
face meetings, and mail.
Communications
The most common mechanisms LHDs used for commu-
nicating with other organizations participating in the
antiviral response were to following: email (56%), blast-
fax (53%), phone (49%), and in-person/face-to-face
meetings (42%). Other commonly cited communications
mechanisms were teleconference (33%), websites (30%),
and the California Health Alert Network, known as
CAHAN (21%). The remaining LHDs indicated that
communication with other agencies around antivirals
did not occur in their jurisdiction or was not applicable
to their health department’s response.
LHDs also used various mechanisms to inform the
public about where eligible persons could obtain antivir-
als. Around half of LHDs indicated that the health
department (57%) or the clinician (45%) were the source
of information for these individuals. Others relied on
pharmacists (32%), the media (16%), or employers (7%).
Table 3 Target groups for treatment with publicly purchased antivirals (n = 28).
Size of Population Served by LHD
Small (<
50,000)
Medium (50,000-
499,999)
Large
(500,000+)
All
LHDs
Eligible Groups n (%) n (%) n (%) n (%)
Uninsured or underinsured persons 3 (75) 11 (69) 3 (38) 17 (61)
Any ill person 2 (50) 3 (19) 5 (63) 10 (36)
Persons at high-risk for medical complications of influenza (e.g. pregnant women) 1 (25) 5 (31) 1 (13) 7 (25)
Persons in an occupation-based target group (e.g. healthcare workers) 1 (25) 4 (25) 0 (0) 5 (18)
Other 0 (0) 3 (19) 1 (13) 4 (14)
Don’t know/Unable to answer 0 (0) 0 (0) 0 (0) 0 (0)
Total 41 6 8 2 8
Among the twenty-eight local health departments (LHDs) reporting that publicly purchased antivirals could be used for treatment, Table 3 summarizest h e
groups eligible for antiviral treatment with publicly purchased antivirals, stratified by size of population served by LHD
**Indicates statistically significant difference with respect to population size served by LHD (Fisher’s exact test, p < .05)
Table 4 Target groups for prophylaxis with publicly purchased antivirals (n = 25).
Size of Population Served
Small (<
50,000)
Medium (50,000-
499,999)
Large
(500,000+)
All
LHDs
Eligible Group n (%) n (%) n (%) n (%)
Household members of persons with H1N1 influenza 3 (100) 10 (77) 4 (44) 17 (68)
Persons at high-risk for medical complications of influenza (e.g. pregnant women) 3 (100) 4 (31) 5 (56) 12 (48)
Healthcare workers 2 (67) 4 (31) 3 (33) 9 (36)
Other first responders 2 (67) 1 (8) 1 (11) 4 (16)
Household members of healthcare workers 1 (33) 0 (0) 1 (11) 2 (8)
Other 0 (0) 3 (23) 3 (33) 6 (24)
Don’t know/Unable to answer 0 (0) 2 (15) 2 (22) 4 (16)
Total 31 39 2 5
Among the twenty-five local health departments (LHDs) reporting that publicly purchased antivirals could be used for pre- or post-prophylaxis, Table 4
summarizes the groups eligible for prophylaxis with publicly purchased antivirals, stratified by size of population served by LHD
**Indicates statistically significant difference with respect to population size served by LHD (Fisher’s exact test, p < .05)
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public because they perceived antiviral need to be low.
Only six LHDs found that there were stakeholder
groups with whom they had to establish communica-
tions for the antiviral response that had not been origin-
ally planned. These stakeholder groups included: smaller
clinics, retail pharmacies, certain minority populations,
community clinics, local school districts, community
based organizations, state correctional facilities, and
indigent populations.
Antiviral challenges for LHDs
LHDs were asked about antiviral challenges faced and
feedback received during the H1N1 influenza response.
In terms of challenges, LHDs were asked to identify
issues that were problematic early and later during the
pandemic response. “Early” was defined as April to June
2009 and “Later” was defined as July 2009 onward.
These challenges are presented in Figure 1.
Changes in antiviral guidance and multiple sources of
information about antivirals presented a serious chal-
lenge to LHDs. This was the most widely cited issue
both early and late in the pandemic, and was described
as ‘very challenging’ by more than a third of health
departments. One LHD noted, “Changing guidance
made it difficult to determine appropriate recipients.”
Other participants indicated that state and federal anti-
viral guidance during H1N1 differed from what they had
anticipated, particularly with respect to the target popu-
lation for stockpiled antivirals. This discrepancy required
their health departments to revise their planned activ-
ities to support this strategy. As several respondents
indicated,
“The drugs from the SNS were originally intended to
[be] used only when the drugs were no longer avail-
able through the commercial market. During the
H1N1 epidemic the state required that we make the
drugs available to people who were unable to afford
the meds.”
“The state’s late decision to make the SNS antivirals
available on a compassionate basis...created a great
deal of trouble for my department.”
“....had this event been more widespread, guidance
from the state could have caused considerable issues
related to the first responder community.”
Shortages of pediatric antivirals and staffing issues also
remained significant challenges for LHDs throughout
the pandemic. The staffing issues were highlighted by
Figure 1 Antiviral challenges reported by Local Health Departments, by time period (n = 44). Proportion of LHDs reporting each antiviral
challenge, by time period (April to June 2009 and June 2009 onward). Among those LHDs reporting a challenge, those issues reported to be
“very challenging” by 40% or more respondents are marked by an asterisk.
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“H1N1 served as a ‘dry run’ for a more severe pan-
demic. Had we been faced with the need to distribute
antiviral drugs to multiple health care and other
venues, to a large percentage of our population, over
a prolonged period of time, we would have been
severely challenged to do so in a secure, accountable,
consistent, and equitable manner. Given decreasing
public health resources, I do not foresee an improve-
ment in our capacity to do this anytime in the near
future.”
Early in the pandemic, the main challenges centered
on ramping up response efforts, such as: determining
uses and target groups for antivirals, ascertaining infor-
mation about antiviral availability in the commercial
market, finding temperature-appropriate storage, and
managing confusion about the use of public versus pri-
vate stockpile antivirals. All challenges were cited less
frequently during the later time period, with the excep-
tion of relabeling antivirals, which was mentioned twice
as frequently in the later time period.
For those LHDs experiencing each challenge, the
issues most likely to be reported as ‘very challenging’
were staffing and personnel issues, changing antiviral
guidance and multiple sources of information, and
administrative hurdles (these “very challenging” issues
are marked with an asterisk in Figure 1). An example of
the type of administrative hurdles faced by LHDs was
illustrated by one respondent,
“We [the LHD] were advised [by the county] ...that
the county would need to consider rapid purchase of
antivirals for protection of essential county workers
a n dp o s s i b l yh e a l t hc a r ew o r k e r s .W ew e r ea s k e dt o
develop a special agreement to have local pharmacies
make the purchase investment and guarantee them
employee utilization and billing of insurance. At the
start of the pandemic, this additional administrative
task to avoid a sizeable county expenditure in anti-
virals for ongoing prophylaxis was an added task for
our small health department.”
Feedback from community partners
LHDs reported receiving negative feedback from com-
munity partners regarding a number of issues related to
antivirals (Table 5). The most frequently mentioned
issues centered on confusion around appropriate uses
and target groups for antivirals and especially publicly
purchased antivirals.
Private clinicians and hospital/healthcare facilities
were the most frequently cited sources of negative feed-
back, reported by 30% and 16% of LHDs respectively.
LHDs that received negative feedback from these enti-
ties commonly also reported negative feedback in the
following areas: confusion regarding clinical guidance
for antiviral use, dissatisfaction regarding which patients
should receive publicly purchased antivirals, and confu-
sion regarding the use of the public versus private
sources of antivirals. Medium sized health departments
(those serving populations between 50,000-499,999 per-
sons) were more likely to report hearing negative feed-
back regarding antiviral availability (Fisher’s Exact test, p
< 0.05).
Only five LHDs reported difficulties or concerns in
providing antivirals to specific populations. The popula-
tions noted by respondents included homeless/transient
populations, undocumented persons, and pregnant
women. One respondent described how reimbursement
issues in Medi-Cal (California’s state Medicaid insurance
program for the poor and underserved) made it difficult
to reach pregnant women early in the pandemic,
“...We had issues in the beginning with Medi-Cal
patients namely pregnant women that did not get
access to the stockpiled antivirals because Medi-Cal
took so long to change their formulary and a commu-
nication (or other) issue related to getting the women
Table 5 Negative feedback received by LHDs from community partners (n = 44)
Feedback n (% of LHDs)
Confusion regarding clinical guidance for antiviral use 18 (41)
Confusion regarding the use of public vs. private stockpile antivirals 11 (25)
Dissatisfaction regarding which patients should receive antivirals from public stockpile 11 (25)
Antiviral availability 10 (23)**
Administrative challenges associated with antivirals 10 (23)
Burdensome paperwork associated with tracking antiviral utilization 4 (9)
Difficulty determining whether local stockpiles had been depleted 3 (7)
Reported misuse of publicly purchased antivirals 2 (5)
Antiviral storage or security 1 (2)
**Indicates statistically significant difference with respect to population size served by LHD (Fisher’s exact test, p < .05)
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remedied when Medi-Cal changed their formulary.”
LHDs also noted positive experiences working with
the state health departments, including,
“The antiviral acquisition, allocation, distribution,
and dispensing was probably the smoothest [part of
the] response during the H1N1 campaign. State did a
great job getting them out to the LHD’sa sw e l la s
retrieving them.”
Discussion
While recent research has demonstrated the clinical
importance of antivirals during the H1N1 influenza
response [17-19], the role public health agencies in the
management of these drugs at the local level has not
been well studied. To the best of our knowledge, this is
the first study to examine the antiviral activities carried
out by LHDs during the H1N1 influenza response using
a representative sample from a large geographic area. A
major finding of this report is that, while the number of
publicly purchased antivirals dispensed was limited in
most communities (fewer than 10% of LHDs reported
that more than 250 courses were dispensed in their jur-
isdiction), LHDs nevertheless drew on their previous
work and engaged in a number of antiviral activities.
LHDs successfully coordinated with the state health
department to receive antivirals from the SNS, made
decisions regarding when and where these antivirals
would be dispensed within their community, determined
which groups would be eligible for these antivirals, allo-
cated and distributed antivirals to dispensing sites for
the purpose of reaching target groups, developed sys-
tems for verifying eligibility for antivirals and tracking
antiviral utilization, and provided guidance to the clini-
cal community.
This study also documents specific challenges pre-
sented by the H1N1 pandemic that were faced, and
overcome, by LHDs. Our research corroborates and
compliments a recent qualitative investigation on this
topic, conducted by National Association of County and
City Health Officials (NACCHO) researchers [20]. Using
different methods, both studies find that LHDs had diffi-
culty reconciling multiple sources and versions of anti-
viral guidance from state and federal agencies, and that
this was a major challenge at the local level. This was
not only the most commonly reported difficulty in our
respondents; it was also one of the most likely to be
characterized as “very challenging.” NACCHO research-
ers aptly describe two potential contributors to confu-
sion at the local level that appear to be supported by
our findings. First, federal antiviral guidance during the
H1N1 response primarily focused on clinical recommen-
dations for antiviral use, and did not directly address
how public stockpiles should be used. Second, clinical
antiviral guidance changed during the course of the pan-
demic, which placed a greater emphasis on the use of
antivirals for early treatment rather than post-exposure
prophylaxis later in the pandemic [20].
Our research also demonstrates that the recom-
mended uses and recipients of publicly purchased anti-
virals during the H1N1 response differed from what
LHDs had anticipated in their pre-pandemic plans, and
that this resulted in additional difficulties. During the
2009 H1N1 pandemic, antivirals were generally available
through normal wholesale and retail markets; as a result,
the State health department recommended that LHDs
use publicly purchased drugs for the treatment of unin-
sured or underinsured persons and for communities
experiencing shortages [3,21]. For many health depart-
ments, this represented a significant shift in their pre-
pandemic antiviral implementation strategy, which had
focused on the use of publicly purchased antivirals for
treatment of ill persons once retail supplies had been
depleted and that had emphasized the role of antivirals
in protecting healthcare workers and other first respon-
ders [4]. As a consequence, LHDs revised their plans to
support these new strategies, though implementing and
communicating these strategies caused a strain on some
local health departments and community partners.
Another outcome with particular relevance to public
health planning is the effect of staffing and personnel
shortages on the public health antiviral response.
Among the nineteen agencies that cited staffing issues
as a challenge during their antiviral response, nearly half
found this to be “very challenging.” These findings are
consistent with the documented workforce reductions in
local public health since 2008 [22]. As noted by one par-
ticipant, current public health resources are insufficient
for local health agencies to confidently deliver antiviral
services in a “secure, accountable, consistent, and equita-
ble manner” during a pandemic with a larger scope or
greater severity. These concerns should be taken into
account in the future development of antiviral and med-
ical countermeasure plans and policies.
Public health systems researchers have noted that var-
iations in availability of community resources and com-
munity preferences will influence how public health
services will be implemented [23]. In this study we
observed great variability in the approaches used by
LHD to manage publicly purchased antiviral drugs. It is
expected that some of this variability is attributable to
differences in the circumstances faced by LHDs (e.g.
influenza illness incidence, community demographics,
availability of antivirals in the retail market) while other
variation is due to differences in disease control and
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study to evaluate the effectiveness of different
approaches; however, the findings may inform prepared-
ness conversations regarding which variations in practice
are seen as beneficial and adaptive and which areas
might benefit from uniformity. State and local health
departments, in California and elsewhere, can study
these variations in practice and select models and pro-
mising practices to be included in their response
planning.
Lastly, this report builds upon the Association of State
and Territorial Health Officials (ASTHO) assessment of
early experiences of state and territorial health depart-
ments in receiving and distributing antivirals from the
SNS [24]. Because state and local public health agencies
serve different roles and functions in the antiviral
response, there is a demonstrated need to document
activities at both levels [10,25,26]. Whereas the ASTHO
research describes how publicly purchased antivirals
were allocated and deployed from the SNS and then dis-
tributed and received at the state-level in California, our
research tracks these antivirals into communities and
further explicates how LHDs managed and directed this
resource.
Limitations
There are several limitations to this study. First, we
chose to permit only one response per LHD and allowed
anyone within the LHD to respond. Thus, we received
responses from SNS coordinators, health officers and
other LHD personnel. It is possible that SNS coordina-
tors and other health department staff, especially health
officers, experienced the 2009 H1N1 influenza pandemic
differently given their different roles. To account for
this, we gave LHDs the flexibility of choosing the person
who was most familiar with their antiviral response.
Given that ninety eight percent of respondents stated
that they knew “al o t ” about their agency’s antiviral
response activities, we consider their perspectives to be
a valid representation of the LHDs’ experience.
A second limitation is the number of LHDs repre-
sented in the study. While this sample includes health
departments that represent nearly three-quarters of the
40 million residents in California - our unit of analysis
is the health department, resulting in a small absolute
number of cases. Furthermore, the communities served
by these LHDs differ dramatically with respect to orga-
nizational and demographic factors. For example, the
smallest health department in California represents
1,200 individuals and the largest serves over 8 million.
Because of these differences, we present some of our
results stratified by the size of the population served by
the LHD. However, once the data are divided by popula-
tion size (or any other community characteristics of
interest), the number of health departments represented
in each stratum is very small, recommending caution in
making strong inferences about any of the observed
differences.
Lastly, because this research focused on LHDs in Cali-
fornia, it is possible that the findings are unique to this
state. However, given concurrence of our research find-
ings with previous qualitative work with a wider geo-
graphic scope [20], we believe these results are more
broadly applicable beyond California. To improve our
understanding of the role of LHDs in the management
of antivirals, this work should be replicated in a state
with a different organizational, political, or authority
structure is in place, which might be expected to contri-
bute to different experiences at the local level (e.g. a
large state with a centralized public health authority)
[27]. Additional studies from other nations that also
used publicly purchased antivirals during the H1N1
influenza response, particularly those with different poli-
cies on antiviral drug use, would cast important light on
this issue.
Conclusion
Prior to 2009, state and federal agencies made substan-
tial investments in antiviral drugs for use during a influ-
enza pandemic, including the purchase of nearly 81
million courses of antiviral drugs. The large-scale
deployment of this asset during the H1N1 influenza
response provides us unique learning opportunity
regarding the public health role in the management of
antiviral activities at the local level, an area of the H1N1
influenza response that has not been well studied.
Results of this study therefore offer an important
descriptive account of LHD management of publicly
purchased antivirals in California, and provide practi-
tioners, policy makers, and academics with a practice-
based assessment of these events. The issues raised and
the challenges faced by LHDs during H1N1 should be
leveraged to inform public health planning for future
pandemics and other emergency events that require
medical countermeasure dispensing activities.
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